// App-Quantinova.ai

: Early Administration of Partially HLA Matched Third Party Virus-Specific T-Cells in Conjunction with Antiviral Treatment for Initial Viral Infection after Allogeneic Stem Cell Transplant Is Safe and Leads to High Rates of Viral Control

Researchers

Presenter

  • Wei Jiang

Principal Investigators

  • Gaurav Sutrave

  • Selmir Avdic

  • Leighton Edward Clancy

  • Shafqat Inam

  • Elissa Atkins

  • Caroline M Bateman

  • Adrian Gabriel Selim

  • Vicki Antonenas

  • Janine Street

  • Renee Simms

  • Peter J. Shaw

  • David Ritchie

  • Emily Blyth

  • David J Gottlieb

Medical Centers

  • The Children's Hospital at Westmead, The Sydney Children's Hospitals Network, Westmead, Australia

  • Department of Haematology, Westmead Hospital, Sydney, Australia

  • Westmead Hospital, University of Sydney, Sydney, Australia

  • Haematology Department, Royal Melbourne Hospital, Melbourne, Australia

  • Westmead Institute for Medical Research, University of Sydney, Sydney, Australia

  • Westmead Hospital, Sydney Cellular Therapies Laboratory, Sydney, Australia

  • Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia

Locations

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Granulocyte colony-stimulating factor

  • Major Histocompatibility Complex, Class I, A

  • Major histocompatibility complex, class II, DR beta 1

Drug/Treatment

  • Filgrastim

Outcome

  • N/A

Study Design

  • Safety

  • Single Arm

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved